MHRA

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD). Details On Trials Compass...

Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) to treat severe AUD. The passport...

Small Pharma Inc. (OTCQB: DMTTF), a biotech company that develops short-acting psychedelic-assisted therapies for depression, received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Research Ethics Committee to begin a Phase 1 clinical study...

UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used to get the London-based startup fully operational. Investors of the seed funding...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc. (OTCQB: PSYGF)’s application to assess the efficacy and safety of psilocybin-assisted psychotherapy compared to psychotherapy alone for treating adjustment disorder following an incurable...

Biotech drug discovery firm Mindset Pharma Inc. (OTCQB: MSSTF) develops next-generation psychedelic and non-psychedelic medicines for neuropsychiatric and neurological disorders. To pursue their goal it received scientific advice from the UK Medicines and Healthcare Products Regulatory Agency...

A group of 15 top psychiatrists are addressing the Royal College of Psychiatrists’s president Dr. Adrian James to back the campaign calling for the nation’s Home Office department to move psilocybin from Schedule 1 to Schedule 2, which would remove "unnecessary and burdensome...